RU2009123930A - Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4 - Google Patents
Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4 Download PDFInfo
- Publication number
- RU2009123930A RU2009123930A RU2009123930/04A RU2009123930A RU2009123930A RU 2009123930 A RU2009123930 A RU 2009123930A RU 2009123930/04 A RU2009123930/04 A RU 2009123930/04A RU 2009123930 A RU2009123930 A RU 2009123930A RU 2009123930 A RU2009123930 A RU 2009123930A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- alkoxy
- heterocyclyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 20
- BJLUORNGPCXNHM-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CN=C2C(=O)NC(=O)NC2=C1 BJLUORNGPCXNHM-UHFFFAOYSA-N 0.000 title 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 133
- 125000003118 aryl group Chemical group 0.000 claims abstract 44
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 42
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 27
- 229910052736 halogen Inorganic materials 0.000 claims abstract 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 17
- -1 cyano, hydroxy Chemical group 0.000 claims abstract 13
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 4
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims abstract 3
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000005110 aryl thio group Chemical group 0.000 claims abstract 2
- 125000005368 heteroarylthio group Chemical group 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 150000002367 halogens Chemical group 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- FNNHJKFSYIKHHF-MEKGRNQZSA-N C1CN(C)CCCN1CC1=CC=C(C=2C=C(C=CC=2)N2C(N([C@H]3CC[C@H](CC3)NC(=O)C=3N=C(C)C=CC=3)C(=O)C3=CC(F)=CN=C32)=O)C=C1 Chemical compound C1CN(C)CCCN1CC1=CC=C(C=2C=C(C=CC=2)N2C(N([C@H]3CC[C@H](CC3)NC(=O)C=3N=C(C)C=CC=3)C(=O)C3=CC(F)=CN=C32)=O)C=C1 FNNHJKFSYIKHHF-MEKGRNQZSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- GBRWFYVQSLTRSG-KRKINAOUSA-N C=1C(O)=CC=C(C=2C=C(C=CC=2)N2C(N([C@H]3CC[C@H](CC3)NCC=3N=C4C=CC(F)=CN4C=3)C(=O)C3=CC(F)=CN=C32)=O)C=1CN1CCOCC1 Chemical compound C=1C(O)=CC=C(C=2C=C(C=CC=2)N2C(N([C@H]3CC[C@H](CC3)NCC=3N=C4C=CC(F)=CN4C=3)C(=O)C3=CC(F)=CN=C32)=O)C=1CN1CCOCC1 GBRWFYVQSLTRSG-KRKINAOUSA-N 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- 0 *c1cccc(N(c2ncc(*)cc2C(N2C(CC3)CCC3NC(c3c[n](cc(*)cc4)c4n3)=O)=O)C2=O)c1 Chemical compound *c1cccc(N(c2ncc(*)cc2C(N2C(CC3)CCC3NC(c3c[n](cc(*)cc4)c4n3)=O)=O)C2=O)c1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Abstract
1. Соединение формулы (I): ! , ! где: ! А представляет собой N или СА1; ! Е представляет собой N или СЕ1; ! W представляет собой (CH2)n; ! Y представляет собой (CH2)р; ! n и р независимо равны 0 или 1; ! R1 представляет собой арил или гетероарил, каждый из которых замещен одной или более чем одной из групп: СО2Н, арил, гетероарил, (C1-6алкил)NR39R40, С(O)NНарил, С(O)N(C1-6алкил)(арил(C1-6алкил)), С(O)NНгетероарил, С(O)NНгетероциклил, C(O)NH(CH2)vNH2, C(O)NH(CH2)vNHCO2(C1-6алкил), С(O)NH((C1-4алкил)арил), С(O)N(C1-4алкил)((C1-4алкил)арил), (C1-6алкил)NHC(O)(C1-6алкокси), гетероциклил(C1-4алкокси), СН=СН(арил), С.С(арил), арил(C1-4алкил), гетероарил(C1-4алкил), арилокси, гетероарилокси, арилтио, гетероарилтио, СН=СН(гетероарил) или С.С(гетероарил); и каждый из которых возможно может быть дополнительно замещен галогеном, циано, гидрокси, C1-4алкилом, C1-4алкокси, CF3, OCF3, C1-4алкилтио, S(O)(C1-4алкил), S(O)2(C1-4алкил) или СО2(C1-4алкил); ! или R1 представляет собой арил(C1-4алкил) или гетероарил(С-1-4алкил), каждый из которых возможно замещен галогеном, циано, гидрокси, C1-4алкилом, C1-4алкокси, CF3, OCF3, C1-4алкилтио, S(O)(C1-4алкил), S(O)2(C1-4алкил), СО2Н, СО2(C1-4алкил), С(O)NНарил, C(O)NH(CH2)vNH2, C(O)NH(CH2)vNHCO2(C1-6алкил), арилом, гетероарилом, СН=СН(арил), С.С(арил), СН=СН(гетероарил) или С.С(гетероарил); ! или R1 представляет собой С5-7циклоалкил, возможно замещенный гидрокси, C1-4алкилом, СО2Н, СО2(C1-4алкил), арилом или гетероарилом; ! или R1 представляет собой С1-10алкил; ! или R1 представляет собой C1-6алкил, замещенный группой NR47R48; ! или R1 представляет собой гетероциклил, возможно замещенный C1-6алкилом, арилом или гетероарилом; ! при условии, что R1 не представляет собой: ! , ! где: ! Х представляет собой S, S(O) или S(O)2; и m равно 0 или 1; ! где арильные или гетероарильные заместители R1 возмож�
Claims (17)
1. Соединение формулы (I):
где:
А представляет собой N или СА1;
Е представляет собой N или СЕ1;
W представляет собой (CH2)n;
Y представляет собой (CH2)р;
n и р независимо равны 0 или 1;
R1 представляет собой арил или гетероарил, каждый из которых замещен одной или более чем одной из групп: СО2Н, арил, гетероарил, (C1-6алкил)NR39R40, С(O)NНарил, С(O)N(C1-6алкил)(арил(C1-6алкил)), С(O)NНгетероарил, С(O)NНгетероциклил, C(O)NH(CH2)vNH2, C(O)NH(CH2)vNHCO2(C1-6алкил), С(O)NH((C1-4алкил)арил), С(O)N(C1-4алкил)((C1-4алкил)арил), (C1-6алкил)NHC(O)(C1-6алкокси), гетероциклил(C1-4алкокси), СН=СН(арил), С.С(арил), арил(C1-4алкил), гетероарил(C1-4алкил), арилокси, гетероарилокси, арилтио, гетероарилтио, СН=СН(гетероарил) или С.С(гетероарил); и каждый из которых возможно может быть дополнительно замещен галогеном, циано, гидрокси, C1-4алкилом, C1-4алкокси, CF3, OCF3, C1-4алкилтио, S(O)(C1-4алкил), S(O)2(C1-4алкил) или СО2(C1-4алкил);
или R1 представляет собой арил(C1-4алкил) или гетероарил(С-1-4алкил), каждый из которых возможно замещен галогеном, циано, гидрокси, C1-4алкилом, C1-4алкокси, CF3, OCF3, C1-4алкилтио, S(O)(C1-4алкил), S(O)2(C1-4алкил), СО2Н, СО2(C1-4алкил), С(O)NНарил, C(O)NH(CH2)vNH2, C(O)NH(CH2)vNHCO2(C1-6алкил), арилом, гетероарилом, СН=СН(арил), С.С(арил), СН=СН(гетероарил) или С.С(гетероарил);
или R1 представляет собой С5-7циклоалкил, возможно замещенный гидрокси, C1-4алкилом, СО2Н, СО2(C1-4алкил), арилом или гетероарилом;
или R1 представляет собой С1-10алкил;
или R1 представляет собой C1-6алкил, замещенный группой NR47R48;
или R1 представляет собой гетероциклил, возможно замещенный C1-6алкилом, арилом или гетероарилом;
при условии, что R1 не представляет собой:
где:
Х представляет собой S, S(O) или S(O)2; и m равно 0 или 1;
где арильные или гетероарильные заместители R1 возможно замещены галогеном, циано, гидрокси, SH, C1-4алкилом, C1-4алкокси, CF3, OCF3, C(O)H, C1-6алкилтио, S(O)(C1-6алкил), S(O)2(C1-6алкил), СО2Н, СО2(C1-6алкил), NR41R42, C1-6алкилом (который возможно замещен галогеном, ОН, СО2Н, NR29R30, NHC(O)O(C1-6алкил), OS(O)2(C1-6алкил) или гетероциклилом), C1-6алкокси (который возможно замещен галогеном, ОН, СО2Н, NR35R36 или гетероциклилом), С3-6циклоалкилом (который возможно замещен галогеном, ОН, СО2Н, NR37R38 или гетероциклилом) или гетероциклилом;
v равно 1, 2, 3 или 4;
R2 представляет собой NR50C(O)R3 или NR4R5;
R3 представляет собой C1-6алкил {возможно замещенный гидроксилом, C1-6алкокси, NR7R8, гетероциклилом {который возможно замещен оксо, гидрокси, C1-6алкилом, СО2(C1-6алкил), арилом, гетероарилом, арил(C1-4алкил), гетероциклилом или С(O)(C1-4алкил)фенилом}, арилом, гетероарилом, С3-7циклоалкилом, С3-7циклоалкил(C1-4алкил), СО2Н, СО2(C1-6алкил), арил(C1-4алкокси), арил(C1-6алкилтио), S(O)2(C1-6алкил), NHC(O)гетероарилом или NHC(O)R6}, C1-6алкокси, С3-6циклоалкил {возможно замещенный гидроксилом, NR43R44 или C1-6алкилом}, гетероциклил {возможно замещенный оксо, гидрокси, C1-6алкилом, амино, арилом, гетероарилом, арил(C1-4алкил), гетероарил(C1-4алкил), гетероциклилом или С(O)(C1-4алкил)фенилом}, арил(C1-4алкил) {замещенный группой амино(C1-4алкил)}, арил или гетероарил;
R4 представляет собой водород, C1-6алкил (возможно замещенный арилом или гетероарилом), арил или гетероарил;
R5 представляет собой водород, C1-6алкил (возможно замещенный гидроксилом, C1-6алкокси, арилом, арилокси, фенил(C1-6алкокси), гетероарилом, С3-10циклоалкилом, СО2Н, CO2(C1-6алкил), NHC(O)O(C1-6алкил) или NHC(O)R6), C1-6алкокси, С3-6циклоалкил (возможно замещенный гидрокси, C1-6алкилом, фенилом, фенил(C1-6алкил), гетероарилом или гетероарил(C1-6алкил)), гетероциклил (возможно замещенный C1-6алкилом, C(O)NH2 или фенил(C1-6алкил)), арил или гетероарил;
R6 представляет собой C1-6алкил или фенил;
R7 и R8 независимо представляют собой водород, C1-6алкил или фенил(C1-4алкил);
вышеуказанные фенильные, арильные и гетероарильные группировки R3, R4, R5, R6, R7 и R8 независимо возможно замещены галогеном, циано, нитро, гидрокси, S(O)qR9, OC(O)NR10R11, NR12R13, NR14C(O)R15, NR16C(O)NR17R18, S(O)2NR19R20, NR21S(O)2R22, C(O)NR23R24, C(O)R25, CO2R26, NR27CO2R28, ОС(O)(C1-6алкил), C1-6алкилом, C1-6гидроксиалкилом, C1-6галогеноалкилом, C1-6алкокси(C1-6)алкилом, амино(C1-4алкил), ди(C1-6)алкиламино(C1-6)алкил, C1-6алкокси, C1-6галогеноалкокси, гидроксил(C1-6алкокси), гетероциклил(C1-6алкокси), C1-6алкокси(C1-6)алкокси, амино(C1-4алкокси), C1-4алкиламино(C1-4алкокси) (который сам возможно замещен фенилом), ди(C1-4алкил)амино(C1-4алкокси), C1-6алкилтио, С2-6алкенилом, С2-6алкинилом, С3-10циклоалкилом (который сам возможно замещен C1-4алкилом или оксо), метилендиокси, дифторметилендиокси, гетероциклилом, гетероциклил(C1-4алкил), фенилом, фенил(C1-4)алкилом, фенокси, фенилтио, фенил(C1-4)алкокси, гетероарилом, гетероарил(C1-4)алкилом, гетероарилокси или гетероарил(C1-4)алкокси; где любая из только что упомянутых фенильных и гетероарильных группировок возможно замещена галогеном, гидрокси, нитро, S(O)r(C1-4алкил), S(O)2NH2, S(O)2NH(C1-4алкил), S(O)2N(C1-4алкил)2, циано, C1-4алкилом, C1-4алкокси, C(O)NH2, С(O)NH(C1-4алкил), С(O)N(C1-4алкил)2, СО2Н, СО2(C1-4алкил), NHC(O)(C1-4алкил), NHS(O)2(C1-4алкил), С(O)(C1-4алкил), CF3 или OCF3;
А1, Е1 и G1 независимо представляют собой водород, галоген, циано, гидрокси, C1-4алкил, C1-4алкокси, CF3 или OCF3;
q и r независимо равны 0, 1 или 2;
если не указано иное, гетероциклил возможно замещен ОН, C1-6алкилом, С3-7циклоалкилом, NR31R32, (С1-6алкил)ОН или (C1-6алкил)NR33R34, NR49CO2(C1-6алкил), CO2(C1-6алкил), С(O)(C1-6алкил), С(O)гетероциклилом, гетероарилом, (C1-6алкил)C(O)NR53R54, (C1-6алкил)C(O)NR55R56, (С1-6алкил)С(O)гетероциклилом или гетероциклилом;
R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27 и R28 независимо представляют собой C1-6алкил {возможно замещенный галогеном, гидрокси или C1-6алкокси}, CH2(С2-6алкенил), фенил {который сам возможно замещен галогеном, гидрокси, нитро, NH2, NH(C1-4алкил), S(C1-4алкил)2, S(O)2(C1-4алкил), S(O)2NH2, S(O)2NH(C1-4алкил), S(O)2N(C1-4алкил)2, циано, C1-4алкилом, C1-4алкокси, C(O)NH2, С(O)NH(C1-4алкил), С(O)N(C1-4алкил)2, СО2Н, СО2(C1-4алкил), NHC(O)(C1-4алкил), NHS(O)2(C1-4алкил), С(O)(C1-4алкил), CF3 или OCF3} или гетероарил {который сам возможно замещен галогеном, гидрокси, нитро, NH2, NH(C1-4алкил), N(C1-4алкил)2, S(O)2(C1-4алкил), S(O)2NH2, S(O)2NH(C1-4алкил), S(O)2N(C1-4алкил)2, циано, C1-4алкилом, C1-4алкокси, C(O)NH2, С(O)NH(C1-4алкил), С(O)N(C1-4алкил)2, СО2Н, СО2(C1-4алкил), NHC(O)(C1-4алкил), NHS(O)2(C1-4алкил), С(O)(C1-4алкил), CF3 или OCF3};
R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R23, R24, R25, R26, R27 и R28 также могут представлять собой водород;
R50 представляет собой водород или C1-6алкил (возможно замещенный группой NR51R52);
R30, R32, R34, R36, R38, R40, R42, R44 или R48 независимо представляют собой водород, C1-6алкил (возможно замещенный гидрокси, C1-6алкокси, C1-6алкилтио, С3-7циклоалкилом (который возможно замещен гидрокси) или NR45R46), С3-7циклоалкил (возможно замещенный группой гидрокси(C1-6алкил)) или гетероциклил (возможно замещенный C1-6алкилом);
R29, R31, R33, R35, R37, R39, R41, R43, R45, R46, R47, R49, R51, R52, R53, R54, R55 и R56 независимо представляют собой водород или C1-6алкил;
или его N-оксид; или его фармацевтически приемлемая соль.
2. Соединение формулы (I) по п.1, где Е представляет собой СЕ1, и Е1 является таким, как определено в п.1.
3. Соединение формулы (I) по п.1, где А представляет собой СН.
4. Соединение формулы (I) по п.1, где G1 представляет собой водород или галоген.
5. Соединение формулы (I) по п.1, где n и р оба равны 1.
6. Соединение формулы (I) по п.1, где А представляет собой СА1; Е представляет собой СЕ1; W и Y оба представляют собой CH2; и G1, А1 и Е1 независимо представляют собой водород или галоген.
7. Соединение формулы (I) по п.1, где R1 представляет собой фенил, замещенный фенилом {который возможно замещен галогеном, гидрокси, СН(O), СО2Н, C1-4алкилом, C1-4алкил(N(C1-4алкил)2), C1-4алкил(NH2), C1-4алкил(NH(C1-4алкил)), C1-4гидроксиалкилом, CF3, C1-4алкилтио, C1-4алкил(гетероциклил) или C1-4алкилNНС(O)O(C1-4алкил)} или гетероциклилом; и гетероциклил возможно замещен C1-6алкилом.
8. Соединение формулы (I) по любому из пп.1-7, где R2 представляет собой NHC(O)R3; и R3 представляет собой C1-4алкил {замещенный NR7R8, гетероциклилом или гетероарилом}, С3-7циклоалкил (возможно замещенный группой NR43R44) или гетероарил; где R7, R8, R43 и R44 являются такими, как определено в п.1; при этом гетероарил возможно замещен галогеном, C1-4алкилом, CF3, C1-4алкокси, OCF3, гетероциклилом или группой амино(C1-4алкил).
9. Соединение формулы (I), которое представляет собой:
6-фтор-N-{цис-4-[6-фтор-2,4-диоксо-1-[4′-(пиперазин-1-илметил)бифенил-3-ил]-1,4-дигидропиридо[2,3-d]пиримидин-3(2Н)-ил]циклогексил}имидазо[1,2-а]пиридин-2-карбоксамид;
6-фтор-N-{цис-4-[6-фтор-2,4-диоксо-1-[4′-(2-пирролидин-1-илэтокси)бифенил-3-ил]-1,4-дигидропиридо[2,3-d]пиримидин-3(2Н)-ил]циклогексил}имидазо[1,2-а]пиридин-2-карбоксамид;
6-фтор-N-{цис-4-[6-фтор-1-(4′-{3-[(3-гидроксипропил)амино]пропил}бифенил-3-ил)-2,4-диоксо-1,4-дигидропиридо[2,3-d]пиримидин-3(2H)-ил]циклогексил}имидазо[1,2-а]пиридин-2-карбоксамид;
6-фтор-3-(цис-4-{[(6-фторимидазо[1,2-а]пиридин-2-ил)метил]амино}циклогексил)-1-[4′-гидрокси-2′-(морфолин-4-илметил)бифенил-3-ил]пиридо[2,3-d]пиримидин-2,4(1Н,3H)-дион; или,
N-{цис-4-[6-фтор-1-{4′-[(4-метил-1,4-диазепан-1-ил)метил]бифенил-3-ил}-2,4-диоксо-1,4-дигидропиридо[2,3-d]пиримидин-3(2H)-ил]циклогексил}-6-метилпиридин-2-карбоксамид;
или его фармацевтически приемлемая соль.
10. Способ получения соединения формулы (I) по п.1, включающий:
а) когда R2 представляет собой NHC(O)R3, удаление защитной группы Boc (трет-бутоксикарбонил) из соединения формулы (II):
где R1, G1, Е, A, Y и W являются такими, как определено в п.1, и взаимодействие продукта, образованного таким образом, с кислотой или производным кислоты формулы (III):
где R3 является таким, как определено для формулы (I), и LG представляет собой уходящую группу; или
б) когда R′, указанный ниже, представляет собой заместитель на фенильной группе R1, проведение следующей реакции сочетания с кислотой R3C(O)OH или подходящим ее производным:
или
в) проведение реакции нижеуказанной циклизации:
с использованием способа, известного в данной области техники.
11. Фармацевтическая композиция, содержащая соединение формулы (I) или его фармацевтически приемлемую соль по п.1 и фармацевтически приемлемый адъювант, разбавитель или носитель.
12. Соединение формулы (I) или его фармацевтически приемлемая соль по п.1 для применения в терапии.
13. Соединение формулы (I) или его фармацевтически приемлемая соль по п.1 в изготовлении лекарственного средства для применения в терапии.
14. Соединение формулы (I) или его фармацевтически приемлемая соль по п.1 для лечения PDE4(фосфодиэстераза 4)-опосредованного болезненного состояния.
15. Способ лечения PDE4-опосредованного болезненного состояния у млекопитающего, страдающего указанным заболеванием или подверженного риску возникновения указанного заболевания, включающий введение млекопитающему, нуждающемуся в таком лечении, терапевтически эффективного количества соединения формулы (I) или его фармацевтически приемлемой соли по п.1.
16. Фармацевтический продукт, содержащий в комбинации первый активный ингредиент, который представляет собой соединение формулы (I) или его фармацевтически приемлемую соль, как описано выше, и по меньшей мере один дополнительный активный ингредиент, выбранный из следующих:
- агонист β2-адренорецептора,
- модулятор функции хемокинового рецептора,
- ингибитор киназной функции,
- ингибитор протеазы,
- стероидный агонист глюкокортикоидного рецептора,
- антихолинергический агент или
- нестероидный агонист глюкокортикоидного рецептора.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88445407P | 2007-01-11 | 2007-01-11 | |
| US60/884,454 | 2007-01-11 | ||
| US94174907P | 2007-06-04 | 2007-06-04 | |
| US60/941,749 | 2007-06-04 | ||
| US95204707P | 2007-07-26 | 2007-07-26 | |
| US60/952,047 | 2007-07-26 | ||
| PCT/GB2008/000061 WO2008084223A2 (en) | 2007-01-11 | 2008-01-10 | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009123930A true RU2009123930A (ru) | 2011-02-20 |
| RU2479584C2 RU2479584C2 (ru) | 2013-04-20 |
Family
ID=39284146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009123930/04A RU2479584C2 (ru) | 2007-01-11 | 2008-01-10 | Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20100204203A1 (ru) |
| EP (1) | EP2106396B1 (ru) |
| JP (1) | JP5369302B2 (ru) |
| KR (1) | KR20090101303A (ru) |
| CN (3) | CN104147011A (ru) |
| AR (1) | AR064889A1 (ru) |
| AU (1) | AU2008204412B2 (ru) |
| BR (1) | BRPI0806689A2 (ru) |
| CA (1) | CA2674647A1 (ru) |
| CL (1) | CL2008000089A1 (ru) |
| CO (1) | CO6210698A2 (ru) |
| EC (1) | ECSP099480A (ru) |
| MX (1) | MX2009007231A (ru) |
| MY (1) | MY162022A (ru) |
| PE (2) | PE20090049A1 (ru) |
| RU (1) | RU2479584C2 (ru) |
| SA (1) | SA08280783B1 (ru) |
| TW (1) | TW200836745A (ru) |
| UY (1) | UY30863A1 (ru) |
| WO (1) | WO2008084223A2 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| US7858663B1 (en) * | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| WO2010004319A1 (en) * | 2008-07-07 | 2010-01-14 | Astrazeneca Ab | Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| JP5558875B2 (ja) * | 2009-03-19 | 2014-07-23 | 日本曹達株式会社 | 新規包接錯体、エポキシ樹脂組成物及び半導体封止用エポキシ樹脂組成物 |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| CN103596431B (zh) * | 2011-03-18 | 2016-06-22 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂 |
| PL2915804T3 (pl) * | 2012-10-31 | 2019-09-30 | Fujifilm Toyama Chemical Co., Ltd. | Nowe pochodne aminy lub ich sole jako inhibitory tnf alfa |
| US9834521B2 (en) * | 2013-03-15 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Choline kinase inhibitors |
| WO2016029216A2 (en) * | 2014-08-22 | 2016-02-25 | Biocryst Pharmaceuticals, Inc. | Method for producing amidine derivatives |
| KR101671404B1 (ko) * | 2014-09-02 | 2016-11-02 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도 |
| US10464896B2 (en) | 2015-06-11 | 2019-11-05 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
| CN106946851B (zh) * | 2017-03-14 | 2019-11-12 | 牡丹江医学院 | 一种用于预防和治疗肾结石的药物 |
| US11685729B2 (en) | 2018-01-19 | 2023-06-27 | Idorsia Pharmaceuticals Ltd. | C5a receptor modulators |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791474A (fr) * | 1971-11-25 | 1973-03-16 | Yamanouchi Pharma Co Ltd | Procede de preparation de derives d'acides cycloalcoylaminoarylcarboxyliques |
| US3838156A (en) * | 1973-03-29 | 1974-09-24 | Sterling Drug Inc | Certain 2-substituted-6-(3 or 4-pyridyl)-nicotinic acid derivatives |
| US4205073A (en) * | 1975-04-30 | 1980-05-27 | Schering Corporation | Anti-diarrheal anilino nicotinic acids and method of using same |
| US4851535A (en) * | 1985-01-23 | 1989-07-25 | Toyama Chemical Co., Ltd. | Nicotinic acid derivatives |
| JPH0629247B2 (ja) * | 1985-01-23 | 1994-04-20 | 富山化学工業株式会社 | 5−フルオロニコチン酸誘導体およびその塩 |
| PH23853A (en) * | 1986-08-21 | 1989-11-23 | Pfizer | Pyridopyrimidinediones |
| US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| TW299333B (ru) * | 1992-12-29 | 1997-03-01 | Takeda Pharm Industry Co Ltd | |
| GB9420168D0 (en) * | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| JPH10298164A (ja) * | 1997-02-27 | 1998-11-10 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体、その製法及びその合成中間体 |
| TWI243055B (en) * | 2000-04-13 | 2005-11-11 | Nippon Zoki Pharmaceutical Co | Pharmaceutical composition for use in treatment of dermatitis |
| JP2002308774A (ja) * | 2001-04-12 | 2002-10-23 | Nippon Zoki Pharmaceut Co Ltd | Iv型ホスホジエステラーゼ選択的阻害剤 |
| DE60333937D1 (de) * | 2002-05-23 | 2010-10-07 | Novartis Vaccines & Diagnostic | Substituierte quinazolinone verbindungen |
| GB0217225D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| US6909002B2 (en) * | 2002-11-22 | 2005-06-21 | Merck & Co., Inc. | Method of preparing inhibitors of phosphodiesterase-4 |
| US20040242583A1 (en) * | 2003-01-20 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use |
| AR049418A1 (es) * | 2004-02-27 | 2006-08-02 | Bayer Pharmaceuticals Corp | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| FR2873118B1 (fr) * | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| MX2007002096A (es) * | 2004-08-31 | 2007-03-29 | Hoffmann La Roche | Derivados de amida de 3-fenil-dihidropirimido[4,5-d] pirimidinonas, su fabricacion y su uso como agentes farmaceuticos. |
| JP2006124387A (ja) * | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
| DE102004050283A1 (de) * | 2004-10-15 | 2006-04-27 | Lanxess Deutschland Gmbh | 4-Aminophenyl-morpholinon-Derivate und deren Herstellung |
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| ATE469649T1 (de) * | 2006-03-23 | 2010-06-15 | Actelion Pharmaceuticals Ltd | Antibiotische cyclohexyl- oder piperidinylcarboxamid-derivate |
| GB0613836D0 (en) * | 2006-07-13 | 2006-08-23 | Univ Greenwich | New medical use of triazine derivatives |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| TW200835497A (en) * | 2007-01-11 | 2008-09-01 | Astrazeneca Ab | Chemical compounds 636 |
| KR101626435B1 (ko) * | 2007-04-10 | 2016-06-01 | 엑셀리시스, 인코포레이티드 | Pi3k 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법 |
| RS52476B (sr) * | 2008-05-13 | 2013-02-28 | Boehringer Ingelheim International Gmbh. | SINTEZA DIHIDROTIENO[3,2-d]PIRIMIDIN DIOLA I SLIČNIH PIRIMIDIN DIOLA |
| US20110166144A1 (en) * | 2008-07-31 | 2011-07-07 | The Regents Of The University Of Michigan | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same |
| WO2010088195A1 (en) * | 2009-01-30 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Azaquinazolinediones useful as chymase inhibitors |
-
2008
- 2008-01-09 SA SA8280783A patent/SA08280783B1/ar unknown
- 2008-01-10 RU RU2009123930/04A patent/RU2479584C2/ru not_active IP Right Cessation
- 2008-01-10 BR BRPI0806689-2A patent/BRPI0806689A2/pt not_active IP Right Cessation
- 2008-01-10 MY MYPI20092895A patent/MY162022A/en unknown
- 2008-01-10 CA CA002674647A patent/CA2674647A1/en not_active Abandoned
- 2008-01-10 KR KR1020097016638A patent/KR20090101303A/ko not_active Ceased
- 2008-01-10 MX MX2009007231A patent/MX2009007231A/es active IP Right Grant
- 2008-01-10 CN CN201410326870.8A patent/CN104147011A/zh active Pending
- 2008-01-10 AU AU2008204412A patent/AU2008204412B2/en not_active Ceased
- 2008-01-10 JP JP2009545224A patent/JP5369302B2/ja not_active Expired - Fee Related
- 2008-01-10 US US12/522,782 patent/US20100204203A1/en not_active Abandoned
- 2008-01-10 US US11/972,182 patent/US20090124596A1/en not_active Abandoned
- 2008-01-10 EP EP08700158.2A patent/EP2106396B1/en active Active
- 2008-01-10 WO PCT/GB2008/000061 patent/WO2008084223A2/en not_active Ceased
- 2008-01-10 UY UY30863A patent/UY30863A1/es not_active Application Discontinuation
- 2008-01-10 CN CN2008800080545A patent/CN101636388B/zh not_active Expired - Fee Related
- 2008-01-10 CN CN2011104106459A patent/CN102532135A/zh active Pending
- 2008-01-11 CL CL2008000089A patent/CL2008000089A1/es unknown
- 2008-01-11 TW TW097101165A patent/TW200836745A/zh unknown
- 2008-01-11 PE PE2008000127A patent/PE20090049A1/es not_active Application Discontinuation
- 2008-01-11 AR ARP080100155A patent/AR064889A1/es unknown
- 2008-01-11 PE PE2012001093A patent/PE20121529A1/es not_active Application Discontinuation
-
2009
- 2009-06-19 CO CO09064186A patent/CO6210698A2/es active IP Right Grant
- 2009-07-02 EC EC2009009480A patent/ECSP099480A/es unknown
-
2011
- 2011-08-03 US US13/197,112 patent/US20120077801A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120077801A1 (en) | 2012-03-29 |
| CO6210698A2 (es) | 2010-10-20 |
| AU2008204412B2 (en) | 2012-03-01 |
| AU2008204412A1 (en) | 2008-07-17 |
| PE20121529A1 (es) | 2012-12-16 |
| US20090124596A1 (en) | 2009-05-14 |
| ECSP099480A (es) | 2009-08-28 |
| WO2008084223A2 (en) | 2008-07-17 |
| EP2106396B1 (en) | 2014-09-24 |
| CL2008000089A1 (es) | 2008-11-03 |
| PE20090049A1 (es) | 2009-03-21 |
| CN104147011A (zh) | 2014-11-19 |
| UY30863A1 (es) | 2008-09-02 |
| US20100204203A1 (en) | 2010-08-12 |
| CN101636388A (zh) | 2010-01-27 |
| EP2106396A2 (en) | 2009-10-07 |
| CA2674647A1 (en) | 2008-07-17 |
| CN102532135A (zh) | 2012-07-04 |
| MX2009007231A (es) | 2009-07-14 |
| KR20090101303A (ko) | 2009-09-24 |
| JP2010515712A (ja) | 2010-05-13 |
| RU2479584C2 (ru) | 2013-04-20 |
| BRPI0806689A2 (pt) | 2015-07-21 |
| JP5369302B2 (ja) | 2013-12-18 |
| CN101636388B (zh) | 2013-09-18 |
| AR064889A1 (es) | 2009-05-06 |
| SA08280783B1 (ar) | 2011-04-24 |
| TW200836745A (en) | 2008-09-16 |
| WO2008084223A3 (en) | 2008-10-02 |
| MY162022A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009123930A (ru) | Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4 | |
| JP2012520861A5 (ru) | ||
| RU2011142182A (ru) | Соединения | |
| JP7763489B2 (ja) | Cdk阻害剤及び医薬品としてのそれらの使用 | |
| IL270219B (en) | Substances with a 2-aminoquinoline skeleton and their uses | |
| HRP20211642T1 (hr) | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, kinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao inhibitori kras g12c za liječenje raka pluća, gušterače ili kolorektalnog karcinoma | |
| WO2018002319A1 (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| ES2967432T3 (es) | Compuestos de imidazo[4,5-b]piridina y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| JP2013529196A5 (ru) | ||
| RU2014126750A (ru) | Ингибиторы тирозинкиназы брутона | |
| ME02202B (me) | Jedinjenja pirolopirimidina kao inhibitori cdk4/6 | |
| US20080275037A1 (en) | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2010513523A5 (ru) | ||
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| KR20010050223A (ko) | Crf 길항제 및 관련 조성물의 용도 | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| US9567333B2 (en) | Triazolopyridyl compounds as aldosterone synthase inhibitors | |
| HRP20130918T1 (hr) | Derivati 4-aminopirimidina kao receptori antagonista histamina h4 | |
| RU2012128551A (ru) | Производные этинила | |
| JP2022550353A (ja) | アザキノリン化合物およびその使用 | |
| IL297332A (en) | Quinoline compounds and compositions for inhibiting ezh2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20140224 |
|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -PC4A- IN JOURNAL: 8-2014 FOR TAG: (73) |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160111 |